Potent 3CLpro inhibitors effective against SARS-CoV-2 and MERS-CoV in animal models by therapeutic treatment
Year: 2023
Type: article
Abstract: Human coronaviruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Middle East respiratory syndrome coronavirus (MERS-CoV) continue to have a significant impact on public health. A limited or lacking therapeutic arsenal for SARS-CoV-2 and MERS-CoV infections calls for an expanded and diversified portfolio of antivirals against these coronavirus infections. We have previously reported a series of small-molecule 3C-like protease (3CLpro) inhibitors against human coronaviruses. In this report, we demonstrated the in vivo efficacy of 3CLpro inhibitors for their broad-spectrum activity against both SARS-CoV-2 and MERS-CoV infections using the fatal animal models. The results suggest that these are promising candidates for further development as broad-spectrum direct-acting antivirals against highly virulent human coronaviruses.
Source: mBio
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,900
Awards: G2260187746, G2960990548, G3239638, G336615015, Norovirus 3CL Protease-Based Anti-norovirus Therapeutics, G6404212674, G6789342282, PPG: SARS-CoV-host cell interactions and vaccine development, G9000060307, G9000105779, G9000210493, Precision Medicine Center for Cystic Fibrosis, Small Molecule Inhibitors Against 3C-Like Protease of SARS-CoV-2
OpenAlex ID: W4390050587